Johnson & Johnson’s Oral IL-23 Receptor Blocker Shows Sustained Efficacy for Up to One Year in PsO
Johnson & Johnson’s investigative oral interleukin (IL)-23 blocker, JNJ-2113, maintains skin clearance in moderate-to-severe plaque psoriasis through one year, according to data from the long-term extension FRONTIER 2 study presented at the American Academy of Dermatology 2024 Annual Meeting in San Diego. In FRONTIER 2, JNJ-2113 maintained high rates of skin clearance through 52 weeks in […]